---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055687"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:10:03.971109+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M

## Summary
- Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).
- Net loss $3.8M ($0.10/share) vs $2.6M loss a year ago; operating loss $3.9M.
- Gross margin 61.2% (down 580bps) on lower ASP, higher warranty reserve and material costs.
- Record backlog 275 units (+56%), includes 83 Medicare Part B; orders/authorizations 180 (+48%).
- Q2 revenue guidance >$5M; FY2024 guidance $28M-$30M; expects operating cash flow breakeven by Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-055687
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017024055687/0000950170-24-055687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017024055687/myo-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055687
- JSON: https://secwatch.observer/filing/0000950170-24-055687.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055687.txt

## Key facts
- Earnings Releases
  MYOMO, INC. reported first quarter ended March 31, 2024 results: revenue $3.8 million, net income $3.8 million, or $0.10 per share. Guidance raised.
  - Period: first quarter ended March 31, 2024
  - Revenue: $3.8 million
  - Net income: $3.8 million, or $0.10 per share
  - Guidance: raised
  - Result: reported results
  source text: Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000095017024055687/0000950170-24-055687-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.